# Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

> **NCT05750589** · PHASE3 · NOT_YET_RECRUITING · sponsor: **iRenix Medical, Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Retinal Disease

## Interventions

- **DRUG:** IRX-101
- **DRUG:** Providone-Iodine

## Key facts

- **NCT ID:** NCT05750589
- **Lead sponsor:** iRenix Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05750589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05750589, "Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05750589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*